Condition: Vasomotor Symptoms · Menopause · Sponsor: Fervent Pharmaceuticals
This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of moderate-to-severe hot flashes in peri- and post-menopausal women over a period of 1-week.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Torrance Clinical Research Institute | Lomita, California, United States | — |
| Long Beach Clinical Trial Services | Long Beach, California, United States | — |
| Provideré Research Inc. | West Covina, California, United States | — |
| Inpatient Research Clinic | Hialeah, Florida, United States | — |
| The Angel Medical Research Corporation | Miami Lakes, Florida, United States | — |
| Suncoast Clinical Research - Pasco County | New Port Richey, Florida, United States | — |
| Cary Medical Group | Cary, North Carolina, United States | — |
| Raleigh Medical Group | Raleigh, North Carolina, United States | — |
| Clinical Research of Philadelphia | Philadelphia, Pennsylvania, United States | — |
| Coastal Carolina Research Center | North Charleston, South Carolina, United States | — |
| ICON Early Phase Services | San Antonio, Texas, United States | — |
| Discovery Clinical Trials - Stone Oak | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05312567